Dual Trigger Compared with Human Chorionic Gonadotropin Alone and Effects on Clinical Outcome of Intracytoplasmic Sperm Injection.
Dual Trigger
Infertility
GnRH Agonist
Human Chorionic Gonadotropin
In vitro Fertilisation Outcome
Journal
International journal of fertility & sterility
ISSN: 2008-076X
Titre abrégé: Int J Fertil Steril
Pays: Iran
ID NLM: 101487941
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
03
09
2020
accepted:
01
02
2021
entrez:
16
12
2021
pubmed:
17
12
2021
medline:
17
12
2021
Statut:
ppublish
Résumé
This study compared outcomes of the standard 6000 IU human chorionic gonadotropin (hCG) trigger with a dual trigger comprised of 6000 IU hCG and 1 mg leuprolide acetate for final oocyte maturation in an intracytoplasmic sperm injection (ICSI) cycle. By convention, ICSI was performed in most cases at the clinic. In this retrospective study, a total of 50 women were included in each arm. Participants were matched for age, indication and number of prior assisted reproduction technology (ART) cycles. Women at risk for ovarian hyperstimulation syndrome (OHSS) were excluded. A flexible gonadotropin releasing hormone (GnRH) antagonist protocol was used and final oocyte maturation was triggered when two leading follicles were >17 mm. Distribution of variables was evaluated visually with histograms. Continuous variables were defined by mean (standard deviation) or median (25 Both groups had similar antral follicle counts, median parity (0) and number of previous failed cycles (0). The median number of oocytes (8 vs. 7), metaphase-two oocytes (6 vs. 5.5), blastocysts (1 vs. 1), clinical pregnancy rates (CPR) (28% vs. 22%), ongoing pregnancy rates (OPR) (22% vs. 20%) and pregnancy rate per transfer (53.3% vs 53.8%) were similar between the dual trigger and hCG only groups, respectively. Dual trigger for oocyte maturation stimulation failed to improve the ICSI outcome.
Sections du résumé
BACKGROUND
BACKGROUND
This study compared outcomes of the standard 6000 IU human chorionic gonadotropin (hCG) trigger with a dual trigger comprised of 6000 IU hCG and 1 mg leuprolide acetate for final oocyte maturation in an intracytoplasmic sperm injection (ICSI) cycle. By convention, ICSI was performed in most cases at the clinic.
MATERIALS AND METHODS
METHODS
In this retrospective study, a total of 50 women were included in each arm. Participants were matched for age, indication and number of prior assisted reproduction technology (ART) cycles. Women at risk for ovarian hyperstimulation syndrome (OHSS) were excluded. A flexible gonadotropin releasing hormone (GnRH) antagonist protocol was used and final oocyte maturation was triggered when two leading follicles were >17 mm. Distribution of variables was evaluated visually with histograms. Continuous variables were defined by mean (standard deviation) or median (25
RESULTS
RESULTS
Both groups had similar antral follicle counts, median parity (0) and number of previous failed cycles (0). The median number of oocytes (8 vs. 7), metaphase-two oocytes (6 vs. 5.5), blastocysts (1 vs. 1), clinical pregnancy rates (CPR) (28% vs. 22%), ongoing pregnancy rates (OPR) (22% vs. 20%) and pregnancy rate per transfer (53.3% vs 53.8%) were similar between the dual trigger and hCG only groups, respectively.
CONCLUSION
CONCLUSIONS
Dual trigger for oocyte maturation stimulation failed to improve the ICSI outcome.
Identifiants
pubmed: 34913299
doi: 10.22074/IJFS.2021.135720.1010
pmc: PMC8530212
doi:
Types de publication
Journal Article
Langues
eng
Pagination
294-299Informations de copyright
Copyright© by Royan Institute. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Hum Reprod Update. 2006 Mar-Apr;12(2):159-68
pubmed: 16254001
Hum Reprod. 1991 Sep;6(8):1088-91
pubmed: 1806566
Gynecol Endocrinol. 2020 Apr;36(4):313-317
pubmed: 31429334
Cochrane Database Syst Rev. 2017 Jan 23;1:CD012103
pubmed: 28111738
Eur J Obstet Gynecol Reprod Biol. 2017 Nov;218:92-98
pubmed: 28957685
J Clin Endocrinol Metab. 1990 Oct;71(4):918-22
pubmed: 2119392
Int J Reprod Biomed. 2017 Jul;15(7):429-434
pubmed: 29177244
Cochrane Database Syst Rev. 2016 Jun 30;(6):CD002118
pubmed: 27357126
Facts Views Vis Obgyn. 2014;6(4):203-9
pubmed: 25593695
Hum Reprod. 2005 Oct;20(10):2887-92
pubmed: 15979994
Fertil Steril. 2013 Oct;100(4):994-1001
pubmed: 23856575
J Reprod Med. 2014 Jan-Feb;59(1-2):63-8
pubmed: 24597289
Reprod Biol Endocrinol. 2019 Jan 4;17(1):7
pubmed: 30609935
Int J Reprod Biomed. 2016 Sep;14(9):557-566
pubmed: 27738657
Fertil Steril. 2013 Nov;100(5):1296-302
pubmed: 23993928
Reprod Biomed Online. 2017 Dec;35(6):701-707
pubmed: 28993105
J Obstet Gynaecol. 2020 Aug;40(6):860-862
pubmed: 31790320
Hum Reprod. 2005 May;20(5):1213-20
pubmed: 15760966
J Clin Endocrinol Metab. 2002 Feb;87(2):709-15
pubmed: 11836309
Fertil Steril. 2008 Oct;90(4):1087-93
pubmed: 18023439
Int J Epidemiol. 2005 Feb;34(1):215-20
pubmed: 15333621
Fertil Steril. 2002 Jun;77(6):1191-5
pubmed: 12057727
Fertil Steril. 2011 Apr;95(5):1655-60
pubmed: 21315341
J Eval Clin Pract. 2005 Feb;11(1):59-65
pubmed: 15660538
Reprod Biomed Online. 2002 Nov-Dec;5(3):232-9
pubmed: 12470520
Hum Reprod. 2013 Sep;28(9):2522-8
pubmed: 23633553
Gynecol Endocrinol. 2019 Jul;35(7):628-630
pubmed: 30810400
Endocr Rev. 2018 Oct 1;39(5):593-628
pubmed: 29982525
Fertil Steril. 2014 Aug;102(2):405-9
pubmed: 24842671
Fertil Steril. 2008 Jul;90(1):231-3
pubmed: 17981269
Reprod Sci. 2017 Aug;24(8):1221-1225
pubmed: 28715965
Fertil Steril. 2000 Sep;74(3):495-7
pubmed: 10973644
Fertil Steril. 1992 Jun;57(6):1254-8
pubmed: 1601147